Experimental CD38 Inhibitor Reaches the Brain and Raises NAD+ in Mice
An experimental oral drug raised NAD+ in mouse brain and lung tissue, advancing a potential brain-health strategy without proving anti-aging benefits.
Summary
Researchers developed experimental drugs that block CD38, an enzyme involved in breaking down NAD+, a molecule essential for cellular energy and repair. Their goal was to create compounds that could reach the brain, where this approach might eventually have applications in brain disorders. By changing the compounds’ chemical structure, they improved activity against mouse and human CD38 in laboratory tests and increased brain exposure in mice. One candidate, called compound 16, raised NAD+ levels in mouse brain and lung tissue after oral doses of 3 to 100 milligrams per kilogram, with larger doses producing greater increases. These findings establish an early drug-development advance, not evidence of improved memory, slower aging, or longer life. The summary is based only on the abstract, which does not provide detailed safety data or demonstrate benefits in humans.
Detailed Summary
CD38 is an enzyme that helps control NAD+, a molecule cells need for energy production and repair processes. Blocking this enzyme could offer a way to influence brain biology relevant to aging. This study describes experimental compounds designed to reach the brain and inhibit CD38, rather than demonstrating that they slow aging or improve memory in humans or treat disease.
The team designed and synthesized a new family of compounds built around three connected rings. They made the structures more rigid to improve inhibition of both mouse and human CD38 in laboratory tests. The compounds work by forming an adduct with ADPR, a molecule involved in NAD+ metabolism, and inhibit CD38 through a mechanism researchers describe as uncompetitive enzyme inhibition.
Further chemical adjustments improved the ratio of unbound drug in mouse brain compared with blood plasma. These efforts produced compound 16, which reached the brain after oral administration. In mice, doses ranging from 3 to 100 milligrams per kilogram increased NAD+ levels in brain and lung tissue in a dose dependent manner. The abstract does not quantify these observed increases.
The findings support CD38 inhibition as a potential drug development strategy for raising NAD+ within the brain. They also show how adjusting molecular structure can improve delivery to this difficult target. However, higher tissue NAD+ is a biological measurement, not proof of better cognition, protection against neurodegeneration, or longer life. No immediate treatment or supplement recommendation follows from these results.
This summary is based on the abstract only. The available information does not report animal numbers, sex, detailed safety findings, duration of effects, or behavioral outcomes. Human testing and sustained benefits are not established. Further studies would need to determine whether this approach improves meaningful health outcomes and whether repeated dosing is safe before any clinical use could be considered.
Key Findings
- Researchers improved laboratory inhibition of both mouse and human CD38 by making the experimental compounds’ structures more rigid.
- Chemical optimization increased unbound brain-to-plasma ratios in mice, supporting improved brain exposure.
- Oral compound 16 increased NAD+ in mouse brain and lung tissue across doses of 3–100 mg/kg.
- Higher doses produced greater NAD+ increases, but the abstract does not report their magnitude.
- The findings do not establish cognitive benefits, slower aging, or a basis for human treatment recommendations.
Methodology
This preclinical medicinal chemistry study used compound synthesis and structure–activity comparisons to optimize CD38 inhibition and brain exposure. Researchers tested activity against mouse and human CD38, assessed unbound brain-to-plasma ratios in mice, and measured brain and lung NAD+ after oral compound 16 dosing.
Study Limitations
This summary is based on the abstract only, which does not provide sample sizes, statistical details, NAD+ effect sizes, or detailed safety findings. The reported tissue measurements do not establish functional benefits, long-term safety, or effectiveness in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: